



SUVEN LIFE SCIENCES LTD

Regd. Off: SDE Serene Chambers, Road No.5, Banjara Hills, Hyderabad - 500 034

Rs. In Lakhs

STATEMENT OF UN-AUDITED STANDALONE & CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER & 9 MONTHS PERIOD ENDED 31st Dec ' 2019.

PART - I		STANDALONE					
Sl. No.	PARTICULARS	For the Quarter Ended			For the 9 months period ended		For the year Ended
		31/12/2019	30/09/2019	31/12/2018	31/12/2019	31/12/2018	31/03/2019
		un-Audited	un-Audited	Un-Audited	Un-Audited	Un-Audited	Audited
		(1)	(2)	(3)	(4)	(5)	(6)
1	Income						
	Revenue from operations	277.26	138.73	210.57	575.47	28,328.98	28,566.97
	Other Income	585.53	238.10	674.08	1,103.92	2,145.47	2,724.50
	Total income	862.79	376.83	884.65	1,679.39	30,474.45	31,291.47
2	Expenses						
	a) Cost of materials consumed	-	-	-	-	7,961.69	7,961.69
	b) Purchases of stock-in-trade	-	-	-	-	-	-
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	-	(929.28)	(929.28)
	d) Employee benefits expense	242.29	420.11	631.42	1,111.35	3,273.19	3,384.64
	e) Finance costs	9.81	10.40	-	30.82	161.19	190.26
	f) Depreciation and amortisation expense	85.50	141.61	98.77	311.63	1,113.79	1,078.97
	g) Manufacturing Exps	-	-	-	-	4,825.55	4,870.09
	h) R & D Exps	638.55	751.18	839.88	2,018.11	4,240.71	5,936.86
	i) Other Expenses	332.57	217.89	107.50	764.61	2,157.30	2,472.86
	Total expenses	1,308.72	1,541.19	1,677.57	4,236.52	22,804.14	24,966.09
3	Profit before exceptional items & Tax (1-2)	(445.93)	(1,164.36)	(792.92)	(2,557.13)	7,670.31	6,325.38
4	Exceptional Items	-	-	-	-	-	-
5	Profit before Tax (3-4)	(445.93)	(1,164.36)	(792.92)	(2,557.13)	7,670.31	6,325.38
6	Tax Expenses						
	a) Current tax	-	-	(165.85)	-	1,597.12	1,298.62
	b) Deferred tax	4.22	(41.11)	204.75	(1,438.16)	1,216.07	1,107.38
7	Net Profit/ (Loss) for the period/year(5-6)	(450.15)	(1,123.25)	(831.82)	(1,118.97)	4,857.12	3,919.38
8	Other Comprehensive Income						
8.a	(i) Items that will not be reclassified to profit or loss	(14.41)	(1.06)	(10.58)	(16.53)	(31.75)	(21.16)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	5.04	0.37	3.77	5.78	11.09	7.39
8.b	(i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
	Total other Comprehensive Income	(9.37)	(0.69)	(6.81)	(10.75)	(20.66)	(13.77)
9	Total Comprehensive Income for the period (7+8)	(459.52)	(1,123.94)	(838.63)	(1,129.72)	4,836.46	3,905.61
10	Paid-up equity share capital	1,272.82	1,272.82	1,272.82	1,272.82	1,272.82	1,272.82
	Face Value of the Share	Re.1.00	Re.1.00	Re.1.00	Re.1.00	Re.1.00	Re.1.00
11	Other Equity	-	-	-	-	-	38,899.39
12	Earning Per Share (EPS) (Face value of Rs.1/- each) :						
	a) Basic	(0.35)	(0.88)	(0.65)	(0.88)	3.82	3.08
	b) Diluted	(0.35)	(0.88)	(0.65)	(0.88)	3.82	3.08
		(not annualised)	(not annualised)	(not annualised)	(not annualised)	(not annualised)	

PART - I		CONSOLIDATED					
Sl. No.	PARTICULARS	For the Quarter Ended			For the 9 months period ended		For the year Ended
		31/12/2019	30/09/2019	31/12/2018	31/12/2019	31/12/2018	31/03/2019
		un-Audited	un-Audited	Un-Audited	Un-Audited	Un-Audited	Audited
		(1)	(2)	(3)	(4)	(5)	(6)
1	Income						
	Revenue from operations	277.26	138.73	210.58	575.47	28,328.98	28,566.97
	Other Income	585.53	238.10	674.08	1,103.92	2,145.47	2,724.50
	Total income	862.79	376.83	884.66	1,679.39	30,474.45	31,291.47
2	Expenses						
	a) Cost of materials consumed	-	-	-	-	7,961.69	7,961.69
	b) Purchases of stock-in-trade	-	-	-	-	-	-
	c) Changes in inventories of finished goods, work-in-progress	-	-	-	-	(929.28)	(929.27)
	d) Employee benefits expense	332.26	459.45	697.68	1,307.70	3,467.15	3,649.29
	e) Finance costs	10.21	10.80	-	31.91	161.93	191.33
	f) Depreciation and amortisation	85.50	141.61	98.77	311.63	1,113.79	1,078.97
	g) Manufacturing Exps	-	-	-	-	4,825.55	4,870.09
	h) R & D Exps	2,370.78	1,564.15	1,369.67	7,538.87	7,282.07	11,894.33
	i) Other Expenses	341.18	223.23	119.68	793.41	2,225.62	2,559.44
	Total expenses	3,139.93	2,399.24	2,285.80	9,983.52	26,108.52	31,275.87
3	Profit before exceptional items , Tax & share in profit/(Loss) of Associates (1-2)	(2,277.14)	(2,022.41)	(1,401.14)	(8,304.13)	4,365.93	15.60
4	Profit before exceptional items , Tax (3+4)	-	-	-	-	-	-
5	Exceptional Items	-	-	-	-	-	-
6	Profit before Tax (5-6)	(2,277.14)	(2,022.41)	(1,401.14)	(8,304.13)	4,365.93	15.60
7	Tax Expenses						
	a) Current tax	-	-	(165.85)	-	1,597.12	1,298.62
	b) Deferred tax	4.22	(41.11)	204.75	(1,438.16)	1,216.07	1,107.39
8	Net Profit/ (Loss) for the period/year(7-8)	(2,281.36)	(1,981.30)	(1,440.04)	(6,865.97)	1,552.74	(2,390.41)
9	Other Comprehensive Income						-
10.a	(i) Items that will not be reclassified to profit or loss	(14.41)	(1.05)	(10.58)	(16.52)	(31.75)	(21.16)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	5.03	0.37	3.77	5.77	11.10	7.39
10.b	(i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
	Total other Comprehensive Income	(9.38)	(0.68)	(6.81)	(10.75)	(20.65)	(13.77)
11	Total Comprehensive Income for the period (9 + 10)	(2,290.74)	(1,981.98)	(1,446.85)	(6,876.72)	1,532.09	(2,404.18)
12	Paid-up equity share capital Face Value of the Share	1,272.82 Re.1.00	1,272.82 Re.1.00	1,272.82 Re.1.00	1,272.82 Re.1.00	1,272.82 Re.1.00	1,272.82 Re.1.00
13	Other Equity	-	-	-	-	-	22,640.16
14	Earning Per Share (EPS) (Face value of Rs.1/- each) :						
	a) Basic	(1.79)	(1.56)	(1.13)	(5.39)	1.22	(1.88)
	b) Diluted	(1.79)	(1.56)	(1.13)	(5.39)	1.22	(1.88)
		(not annualised)	(not annualised)	(not annualised)	(not annualised)	(not annualised)	

NOTES:-

1.The above results were reviewed by Audit Committee of the Board and approved by the Board of Directors' at their Meeting held on 13th Feb 2020 and the same has been reviewed by the Statutory Auditors.

2.The National Company Law Tribunal, Hyderabad Bench vide its order dated January 06,2020 has approved the scheme of arrangement for demerger of CRAMS undertaking of the Company to Suven Pharmaceuticals Limited (SPL) with effect from October 01, 2018 (the appointed date). The Scheme became effective from October 01, 2018. Pursuant to the Scheme, all the assets, liabilities, income and expenses of the CRAMS undertaking have been transferred to SPL from the appointed date.

The impact of discontinued operations are as follows:

(Rs in Lakhs)

Parriculars	Quarter Ended	Quarter Ended	Quarter Ended	For the 9 months Period		Year Ended
	31.12.2019	30.09.2019	31.12.2018	31.12.2019	31.12.2018	31.03.2019
Total Income	18,359.37	27,837.28	12,710.09	66,180.25	12,710.09	37,843.47
Total Expenditure	11,182.17	15,696.76	8,396.01	37,265.19	8,396.01	22,056.76
Profit Before Tax	7,177.20	12,140.52	4,314.08	28,915.06	4,314.08	15,786.71
Tax Expense	1,977.35	3,148.94	868.95	7,231.11	868.95	4,859.28
Profit After Tax	5,199.85	8,991.58	3,445.13	21,683.95	3,445.13	10,927.43

Consequently,the figures in Column (5) & (6) represent Demerged Undertaking & Research and development Business for the period 01-04-2018 to 30-09-2018 (i.e PRE DEMERGER) and figures for the subsequent period 01-10-2018 to 31-12-2018 & 01-10-2018 to 31-03-2019 (POST DEMERGER) in Column (5) & (6) respectively are of Research and development Business as a result of demerger of CRAMS undertaking of the Company to Suven Pharmaceuticals Limited (SPL) with effect from October 01, 2018. To that extent current quarter and nine months numbers are not comparable with previous periods presented.

3. The Company has only one business segment, i.e. Research & Development and does not operate in any other segments. Hence, segment reporting as per IND AS 108 (Operating Segment) is not presented.

4. The Company is in the process of evaluating the impact of newly introduced Sec.115BAA of the Taxation Laws (Amendments) Ordinance , 2019.

5. The corresponding previous period figures have been regrouped / reclassified where ever necessary.

6.The above is an extract of the detailed format of Quarterly/ Annual Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quaterly/Annual Financial Results are available on the websites of the stock exchanges(s) and the listed entity. (www.bseindia.com and www.nseindia.com) and company's website www.suven.com

For SUVEN LIFE SCIENCES LTD

Place : Hyderabad
Date : 13th Feb ' 2020

VENKAT JASTI
Chairman & CEO
DIN: 00278028